Navigation Links
Excipients Help Pharma Extend Product Life, Profits
Date:4/2/2008

NEW YORK, April 2, 2008 /PRNewswire/ -- With their ability to extend product life, excipients are being turned to increasingly as part of Big Pharma's strategy during lean times, and this portends a robust market for them, according to a new report from a major life sciences market research publisher. There are about 1200 excipients on the market, used in all types of pharmaceuticals. This $4.6 billion market has witnessed healthy growth in the past few years and is expected to continue along the same trajectory through 2012, due to increased demand from new drug targets, new biological drugs, new formulations and synthetic agents, according to Kalorama Information's new report Pharmaceutical Excipients for Oral Formulations, 2nd Edition.

Pharmaceutical excipients are substances, other than the pharmacologically active drug or prodrug, which are included in the manufacturing process or are contained in the finished pharmaceutical product dosage form. Excipients provide enhanced functionality to pharmaceuticals, aid in drug development and innovation and help improve patent life, all at a lower cost.

The pharmaceutical industry continues to be weighed down by the pressure to cut costs, by generic competition, and a lack of innovation. In this environment, excipients are becoming a more important aspect in tablet manufacture than they were previously and are even helping to develop innovative drug formulations. For example, innovations in delivery, such as sustained release, allow pharmaceutical companies to extend the patent life on existing products.

"Once they were thought of as fillers, but today the line between active ingredients and excipients has blurred," notes Bruce Carlson, publisher of Kalorama Information. "As companies need to develop cost-cutting strategies, excipients are now thought of as functional materials rather than inactive bulking agents."

Kalorama Information's report Pharmaceutical Excipients for Oral Formulations, 2nd Edition covers five key segments, including binders/fillers, coating agents, disintegrants, lubricants and sweeteners. Profiles of leading excipient producers are included. The information presented is the result of primary research interviews conducted with industry executives, as well as data gathered through secondary research. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Pharmaceutical-Excipients-Oral-1517793/.

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. For more information, contact Andrea Hiller at 212-807-2673 or press@kaloramainformation.com, or visit http://www.kaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has ... with Hercules Technology Growth Capital, Inc. and Hercules ... in financing. --> ... million of financing under the loan and security ...
(Date:2/8/2016)... Novan, Inc. today announced that Director Robert A. Ingram ... In addition, Robert Keegan has been appointed to the ... --> North Carolina . ... of $32.8 million of net proceeds in a private Mezzanine B ... the Research Triangle area of North Carolina . ...
(Date:2/8/2016)... 2016  BioElectronics Corporation (OTC Pink: BIEL), the ... that it is responding to a notice of ... and Exchange Commission posted on the agency website.  ... the Board of BioElectronics Corporation and the Edward ... The Fuqua School of Business, Duke University.   ...
(Date:2/8/2016)... ... February 08, 2016 , ... Bulk food product ... foods at various stages of the production process. Despite frequently inspecting loose product ... products post packaging such as sacks of dry powders. , Mettler-Toledo Product Inspection's ...
Breaking Biology Technology:
(Date:2/3/2016)... Calif. , Feb. 3, 2016 Vigilant ... Police Department in Missouri ... license plate reader (LPR) data from Vigilant Solutions. ... hit-and-run case in which the victim was walking out of a convenience ... parking space next to his vehicle, striking his vehicle ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/1/2016)... 1, 2016 Rising sales of ... global touchfree intuitive gesture control market size ... sales of consumer electronics coupled with new technological advancements ... size through 2020   --> ... new technological advancements to drive global touchfree intuitive gesture ...
Breaking Biology News(10 mins):